DadFinStart your free week
DadFin › Stocks › Healthcare › EDSA

Edesa Biotech, Inc. (EDSA) stock score

Healthcare · Biotechnology · Canada

$1.89 ▼ -2.58% today

9.9
Dad Score, out of 100
poor

Edesa Biotech, Inc. (EDSA) is a Biotechnology company in the Healthcare sector, listed in Canada. On DadFin's weekly run it scores 9.9 out of 100 on the Dad Score, a poor reading that places the business ahead of 10% of the 5,684 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #869 of 956. Its strongest axes are conviction and liquidity; its weakest are valuation and price action.

Scores from the run of Nov 15, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Average
Growth
Average
Price action
Weak
Risk
Below average
Conviction
Above average
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)—
Dividend yield0.00%
Return on capital-57.7%
Operating margin0.0%
Revenue growth (YoY)+0.0%
FCF yield-29.7%
Net debt / EBITDA3.00×
Piotroski F-Score2 / 9
52-week change+11.5%
Market cap$26M
Next earningsDec 10, 2026

What subscribers see on EDSA

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate75.0good$136.6B
REGNRegeneron Pharmaceuticals, Inc.98.6strong$98.8B
MRNAModerna, Inc.31.8weak$90.4B
ARGXargenx SE86.7strong$60.4B
ONCBeOne Medicines AG95.0strong$47.6B
RPRXRoyalty Pharma plc98.2strong$39.9B
RVMDRevolution Medicines, Inc.44.8middling$37.3B
GMABGenmab A/S63.2middling$31.7B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 15, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.